|[April 14, 2014]
Research and Markets: Global Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/sm6dww/recombivax_hb)
has announced the addition of the "Recombivax
HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market
Analysis to 2022" report to their offering.
Recombivax HB [Hepatitis B Vaccine (Recombinant)] is Merck's monovalent
vaccine that protects children, adolescents, and adults against acute
and chronic infections caused by all identified strains of HBV. Merck's
vaccine was the first recombinant vaccin for HBV to be widely
commercialized. Upon its approval and launch in the US in 1986,
Recombivax HB began to replace the first-generation, human
plasma-derived HBV vaccines as the preferred treatment option for active
immunization against acute and chronic HBV infection (CDC, 2012a; FDA,
Overview of Hepatitis B disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on Recombivax HB including product description,
safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Recombivax HB for top eight countries from 2012 to
Sales information covered for the US, France, Germany, Italy, Spain,
UK, Japan and Canada.
Key Topics Covered:
Tables & Figures
Vaccination Recommendations and Coverage Rates
[ InfoTech Spotlight's Homepage ]